OTCMKTS:PFSCF

ProMetic Life Sciences Stock Forecast, Price & News

$5.47
-0.20 (-3.58 %)
(As of 11/15/2019)
Add
Compare
Today's Range
$5.47
Now: $5.47
$5.47
50-Day Range
$5.47
MA: $5.47
$5.47
52-Week Range
$5.47
Now: $5.47
$352.00
Volume200 shs
Average Volume279 shs
Market Capitalization$127.45 million
P/E RatioN/A
Dividend YieldN/A
Beta2.46
Prometic Life Sciences Inc. operates as a biopharmaceutical company with two drug discovery platforms that focuses on unmet medical needs in the field of fibrosis and orphan diseases. Its product pipeline includes PBI-4050, an orally active lead drug candidate for fibrosis; plasminogen, a biopharmaceutical for the treatment of congenital plasminogen deficiency; and intravenous immunoglobulin, a preparation of antibodies purified from plasma donations from healthy individuals. The company was founded in 1992 and is based in Laval, Canada.
ProMetic Life Sciences logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:PFSCF
Previous SymbolNASDAQ:PFSCF
CUSIPN/A
CIKN/A
Phone1-450-781-0115
Employees487
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$36.55 million
Book Value($67.63) per share

Profitability

Net Income$-150,730,000.00
Net Margins-894.02%

Miscellaneous

Market Cap$127.45 million
Next Earnings DateN/A
OptionableNot Optionable

Headlines

ProMetic Life Sciences (OTCMKTS:PFSCF) Stock Price Down 3.6%
March 26, 2021 |  americanbankingnews.com
See More Headlines

MarketRank

Overall MarketRank

0.46 out of 5 stars

Medical Sector

1679th out of 2,019 stocks

Pharmaceutical Preparations Industry

692nd out of 772 stocks

Analyst Opinion: 0.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
$5.47
-0.20 (-3.58 %)
(As of 11/15/2019)
30 days | 90 days | 365 days | Advanced Chart

Receive PFSCF News and Ratings via Email

Sign-up to receive the latest news and ratings for PFSCF and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











ProMetic Life Sciences (OTCMKTS:PFSCF) Frequently Asked Questions

What stocks does MarketBeat like better than ProMetic Life Sciences?

Wall Street analysts have given ProMetic Life Sciences a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but ProMetic Life Sciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How has ProMetic Life Sciences' stock price been impacted by COVID-19 (Coronavirus)?

ProMetic Life Sciences' stock was trading at $5.4670 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, PFSCF stock has increased by 0.0% and is now trading at $5.4670.
View which stocks have been most impacted by COVID-19
.

Who are ProMetic Life Sciences' key executives?

ProMetic Life Sciences' management team includes the following people:
  • Mr. Kenneth H. Galbraith, CEO & Director (Age 56)
  • Mr. Bruce Pritchard, COO & Interim CFO
  • Mr. Patrick Sartore, Chief Legal Officer & Corp. Sec.
  • Mr. Bruce Wendel, Chief Bus. Devel. Officer (Age 65)
  • Dr. John Moran, Chief Medical Officer (Age 73)

Who are some of ProMetic Life Sciences' key competitors?

What is ProMetic Life Sciences' stock symbol?

ProMetic Life Sciences trades on the OTCMKTS under the ticker symbol "PFSCF."

How do I buy shares of ProMetic Life Sciences?

Shares of PFSCF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ProMetic Life Sciences' stock price today?

One share of PFSCF stock can currently be purchased for approximately $5.47.

How much money does ProMetic Life Sciences make?

ProMetic Life Sciences has a market capitalization of $127.45 million and generates $36.55 million in revenue each year.

How many employees does ProMetic Life Sciences have?

ProMetic Life Sciences employs 487 workers across the globe.

What is ProMetic Life Sciences' official website?

The official website for ProMetic Life Sciences is www.prometic.com.

Where are ProMetic Life Sciences' headquarters?

ProMetic Life Sciences is headquartered at 440 Boulevard Armand-Frappier Suite 300, Laval A8, H7V 4B4.

How can I contact ProMetic Life Sciences?

ProMetic Life Sciences' mailing address is 440 Boulevard Armand-Frappier Suite 300, Laval A8, H7V 4B4. The company can be reached via phone at 1-450-781-0115 or via email at [email protected]


This page was last updated on 4/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.